ArticleBMC cancer2023

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.

Dilara Akhoundova Sanoyan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.